Loading...
| Name | Option type | Quality (1-5)↓ | Topics | Created | |
|---|---|---|---|---|---|
Will Alnylam's Vutrisiran receive FDA approval for ATTR-CM by end of 2024?  | Binary | 4 | 4 months ago | ||
Will BridgeBio's Acoramidis receive FDA approval for ATTR-CM by end of 2024? | Binary | 3 | 4 months ago | ||
Will Alnylam's stock price recover to pre-HELIOS-B Phase 3 study announcement levels by end of 2024? | Binary | 3 | 4 months ago | ||
Which drug will lead the market share in 2025: Vutrisiran or Acoramidis? | Categorical | 2 | 4 months ago | ||
Which drug will show superior primary endpoint results in future clinical trials: Vutrisiran or Acoramidis? | Categorical | 2 | 4 months ago | ||
What will be Alnylam's Vutrisiran sales by end of 2025? | Categorical | 2 | 4 months ago |